title: Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders.
abstract: Hypercoagulability can be defined as a condition of procoagulant imbalance due to heightened enzymatic activation of coagulation zymogens, but with no laboratory evidence of fibrin deposition nor clinical signs of thrombosis. The imbalance can be detected by measuring the plasma levels of prothrombin fragment 1 + 2 (F1 + 2), fibrinopeptide A (FPA) and thrombin-antithrombin III (TAT) complexes. The aims of this study were to establish the frequency of existence and biochemical pattern of hypercoagulability in patients with cancer and autoimmune disorders, clinical conditions associated with an increased risk of thrombosis, and to ascertain the most sensitive method for its diagnosis. In approximately one-fourth of the patients hypercoagulability was identified by finding high levels of FPA F1 + 2 or TAT unaccompanied by signs of fibrin deposition (expressed by normal levels of D-dimer). In a smaller proportion of patients (approximately 10%), the concomitant presence of high levels of D-dimer indicated that the activation of the coagulation cascade had gone beyond the stage of heightened enzymatic activity to the point of cross-linked fibrin deposition. Of the markers used to detect hypercoagulability. FPA seems to be the most sensitive, being significantly increased in all clinical conditions studied.
authors.affiliation: Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Institute of Internal Medicine, Milano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Tripodi
authors.forename: P M
authors.initials: PM
authors.lastname: Mannucci
authors.forename: V
authors.initials: V
authors.lastname: Chantarangkul
authors.forename: B
authors.initials: B
authors.lastname: Bottasso
authors.forename: A A
authors.initials: AA
authors.lastname: Arbini
authors.forename: S
authors.initials: S
authors.lastname: Della Bella
authors.forename: R
authors.initials: R
authors.lastname: Scorza
mesh_terms: D000293:Adolescent; D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D001327:Autoimmune Diseases / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000502:physiology*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005344:Fibrinopeptide A / Q000032:analysis; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D008297:Male; D008545:Melanoma / Q000097:blood*; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D011516:Prothrombin / Q000032:analysis; D012878:Skin Neoplasms / Q000097:blood*
chemical_list: D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D005344:Fibrinopeptide A; D000990:Antithrombin III; D011516:Prothrombin; D010447:Peptide Hydrolases